Topics:
autoimmunity, cancer, immunotherapy

On page 500 in the 21 July 2011 issue, ther e is an error in the bottom line of Table 1; “CAR-modified T cells” should have read, “TCR gene-modified T cells.” The corrected table is shown.

Table 1

Immune-mediated toxicities associated with adoptive immunotherapy of cancer

Cell typeSpeciesTarget antigenTumorToxicitiesReference(s)
CTL Mouse (or rat) Pnma-1 Paraneoplastic syndrome (rat) CNS inflammation 80 
CTL Recoverin Fibrosarcoma Retinal dysfunction 81 
CTL with IL-2 and vaccine Various Melanoma Melanocyte destruction, ocular toxicity 8,82 
CD4+ T cells TRP-1 Melanoma Vitiligo 83,84 
Immune T cells CEA Colon Colitis 85 
Transgenic T cells Telomerase Prostate Reduction in B cells 86 
TCR transgenic T cells Various None Pancreatitis, colitis 11 
CAR-modified T cells CD19 Lymphoma Depletion of normal B cells 87,88 
CAR-modified T cells VEGF-R2 Various Various organs, probably the result of cytokine-induced hypotension 89 
TIL and IL-2 Human Various Melanoma Autoimmune thyroiditis, systemic and ocular autoimmunity 90–92 
TIL with lymphodepletion and IL-2 Various Melanoma Vitiligo, uveitis 9,93 
CTL MART-1 Melanoma Melanocyte destruction 94 
TCR gene–modified T cells MART-1, gp100 Melanoma Melanocyte destruction 10 
CAR-modified T cells CAIX RCC Liver toxicity (grade 2-4) in 3 of 7 patients; lower grade in 4 of 7 patients with reduced dosing 14 
CAR-modified T cells CD19 Lymphoma B-cell depletion 15 
CAR-modified T cells Her-2 Colorectal cancer Lung toxicity 17 
TCR gene-modified T cells CEA Colorectal cancer Colitis 19 
Cell typeSpeciesTarget antigenTumorToxicitiesReference(s)
CTL Mouse (or rat) Pnma-1 Paraneoplastic syndrome (rat) CNS inflammation 80 
CTL Recoverin Fibrosarcoma Retinal dysfunction 81 
CTL with IL-2 and vaccine Various Melanoma Melanocyte destruction, ocular toxicity 8,82 
CD4+ T cells TRP-1 Melanoma Vitiligo 83,84 
Immune T cells CEA Colon Colitis 85 
Transgenic T cells Telomerase Prostate Reduction in B cells 86 
TCR transgenic T cells Various None Pancreatitis, colitis 11 
CAR-modified T cells CD19 Lymphoma Depletion of normal B cells 87,88 
CAR-modified T cells VEGF-R2 Various Various organs, probably the result of cytokine-induced hypotension 89 
TIL and IL-2 Human Various Melanoma Autoimmune thyroiditis, systemic and ocular autoimmunity 90–92 
TIL with lymphodepletion and IL-2 Various Melanoma Vitiligo, uveitis 9,93 
CTL MART-1 Melanoma Melanocyte destruction 94 
TCR gene–modified T cells MART-1, gp100 Melanoma Melanocyte destruction 10 
CAR-modified T cells CAIX RCC Liver toxicity (grade 2-4) in 3 of 7 patients; lower grade in 4 of 7 patients with reduced dosing 14 
CAR-modified T cells CD19 Lymphoma B-cell depletion 15 
CAR-modified T cells Her-2 Colorectal cancer Lung toxicity 17 
TCR gene-modified T cells CEA Colorectal cancer Colitis 19 

CTL indicates cytotoxic T lymphocyte; CNS, central nervous system; IL-2, interleukin-2; and TIL, tumor-infiltrating lymphocytes.

View Large
© 2012 by The American Society of Hematology
2012
Sign in via your Institution